EODData

MEMBERSHIP REGISTER LOG IN

FRA, 1ZL: Zai Lab Limited

07 Nov 2025
LAST:

19.40

CHANGE:
 0.40		OPEN:
19.40		HIGH:
19.40		ASK:
0.00		VOLUME:
100
CHG(%):
2.02		PREV:
19.80		LOW:
19.40		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
07 Nov 2519.4019.4019.4019.40100
06 Nov 2521.0021.0019.8019.80100
05 Nov 2522.0022.0022.0022.00100
04 Nov 2522.2022.2022.2022.20100
31 Oct 2521.6021.6021.6021.60100
30 Oct 2522.2022.2021.8021.80100
29 Oct 2521.4021.4021.4021.40100
28 Oct 2522.0022.0022.0022.00100
27 Oct 2522.2022.2022.2022.20100
24 Oct 2523.8023.8023.8023.8010

COMPANY PROFILE

Name:Zai Lab Limited
About:Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam. The company was incorporated in 2013 and is headquartered in Pudong, China.
Sector:Healthcare
Industry:Biotechnology
Address:Building B, Pudong, China, 201203
Website:https://www.zailaboratory.com
ISIN:US98887Q1040
LEI:549300P2UYQ9U5LY1T58

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-8.54 
Forward P/E:-5.64 
PEG Ratio:0.17 
Price to Sales:6.19 
Price to Book:3.19 
Profit Margin:-0.50 
Operating Margin:-0.50 
Return on Assets:-0.14 
Return on Equity:-0.28 
Revenue:371.29M 
Shares:111.27M 
Market Cap:2.159B 

TECHNICAL INDICATORS

MA5:21.008.2%
MA10:21.6211.4%
MA20:23.3420.3%
MA50:25.7432.7%
MA100:28.1645.2%
MA200:28.7848.4%
RSI14:24.44 
WPR14:-100.00 
MTM14:-4.40
ROC14:-0.18 
ATR:0.67 
Week High:22.2014.4%
Week Low:19.400.0%
Month High:29.4051.5%
Month Low:19.4048.4%
Year High:38.0696.2%
Year Low:19.400.0%
Volatility:11.93